These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1441 related articles for article (PubMed ID: 12692607)

  • 21. Long-term follow-up after autologous hematopoietic stem cell transplantation for low-grade non-Hodgkin lymphoma.
    Laudi N; Arora M; Burns LJ; Miller JS; McGlave PB; Barker JN; Ramsay NK; Orchard PJ; Macmillan ML; Weisdorf DJ
    Biol Blood Marrow Transplant; 2005 Feb; 11(2):129-35. PubMed ID: 15682074
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence, clinical pattern, and outcome of CNS involvement in childhood and adolescent non-Hodgkin's lymphoma differ by non-Hodgkin's lymphoma subtype: a Berlin-Frankfurt-Munster Group Report.
    Salzburg J; Burkhardt B; Zimmermann M; Wachowski O; Woessmann W; Oschlies I; Klapper W; Wacker HH; Ludwig WD; Niggli F; Mann G; Gadner H; Riehm H; Schrappe M; Reiter A
    J Clin Oncol; 2007 Sep; 25(25):3915-22. PubMed ID: 17761975
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Peripheral-blood stem-cell transplantation versus autologous bone marrow transplantation in Hodgkin's and non-Hodgkin's lymphomas: a new matched-pair analysis of the European Group for Blood and Marrow Transplantation Registry Data. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
    Majolino I; Pearce R; Taghipour G; Goldstone AH
    J Clin Oncol; 1997 Feb; 15(2):509-17. PubMed ID: 9053472
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical outcome following autologous and allogeneic blood and marrow transplantation for relapsed diffuse large-cell non-Hodgkin's lymphoma.
    Aksentijevich I; Jones RJ; Ambinder RF; Garrett-Mayer E; Flinn IW
    Biol Blood Marrow Transplant; 2006 Sep; 12(9):965-72. PubMed ID: 16920563
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Autologous bone marrow transplantation for non-transformed low-grade non-Hodgkin's lymphoma.
    Cervantes F; Shu XO; McGlave PB; Ramsay NK; Miller WJ; Kersey JH; Weisdorf DJ
    Bone Marrow Transplant; 1995 Sep; 16(3):387-92. PubMed ID: 8535311
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Allogeneic peripheral blood stem cell transplantation for high-risk non-Hodgkin's lymphoma.
    Seropian S; Bahceci E; Cooper DL
    Bone Marrow Transplant; 2003 Oct; 32(8):763-9. PubMed ID: 14520419
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma.
    Kewalramani T; Nimer SD; Zelenetz AD; Malhotra S; Qin J; Yahalom J; Moskowitz CH
    Bone Marrow Transplant; 2003 Oct; 32(7):673-9. PubMed ID: 13130314
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Haemopoietic stem cell transplantation in Australia and New Zealand, 1992-2001: progress report from the Australasian Bone Marrow Transplant Recipient Registry.
    Nivison-Smith I; Bradstock KF; Dodds AJ; Hawkins PA; Szer J
    Intern Med J; 2005 Jan; 35(1):18-27. PubMed ID: 15667464
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Blood and marrow transplantation activity in Europe 1997. European Group for Blood and Marrow Transplantation (EBMT).
    Gratwohl A; Passweg J; Baldomero H; Hermans J
    Bone Marrow Transplant; 1999 Aug; 24(3):231-45. PubMed ID: 10456992
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
    Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
    Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Autologous stem cell transplantation in lymphomas and Hodgkin's disease].
    Greinix HT
    Acta Med Austriaca Suppl; 2000; 52():25-9. PubMed ID: 11261274
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
    Sureda A; Robinson S; Canals C; Carella AM; Boogaerts MA; Caballero D; Hunter AE; Kanz L; Slavin S; Cornelissen JJ; Gramatzki M; Niederwieser D; Russell NH; Schmitz N
    J Clin Oncol; 2008 Jan; 26(3):455-62. PubMed ID: 18086796
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Successful allogeneic bone marrow transplantation for early relapse after autologous bone marrow transplantation in two cases of aggressive high-grade non-Hodgkin's lymphoma.
    Moreau P; Méchinaud F; Mahé B; Le Tortorec S; Rapp MJ; Maisonneuve H; Harousseau JL; Milpied N
    Bone Marrow Transplant; 1996 Sep; 18(3):665-7. PubMed ID: 8879639
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Factors associated with survival in patients with progressive disease following autologous transplant for lymphoma.
    Paltiel O; Rubinstein C; Or R; Nagler A; Gordon L; Deutsch L; Polliack A; Naparstek E
    Bone Marrow Transplant; 2003 Apr; 31(7):565-9. PubMed ID: 12692622
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adult Burkitt's and Burkitt-like non-Hodgkin's lymphoma--outcome for patients treated with high-dose therapy and autologous stem-cell transplantation in first remission or at relapse: results from the European Group for Blood and Marrow Transplantation.
    Sweetenham JW; Pearce R; Taghipour G; Blaise D; Gisselbrecht C; Goldstone AH
    J Clin Oncol; 1996 Sep; 14(9):2465-72. PubMed ID: 8823324
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [5 years of dosage intensification and autologous bone marrow or peripheral stem cell transfusion in malignant lymphoma with a high risk of recurrence].
    Jost LM; Pichert G; Reichlin M; Müller E; Jacky E; Honegger HP; Gmür J; Stahel RA
    Schweiz Med Wochenschr; 1993 May; 123(18):932-40. PubMed ID: 8098878
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Allogeneic stem cell transplantation for the non-Hodgkin's lymphomas and Hodgkin's disease.
    Hale GA; Phillips GL
    Cancer Treat Rev; 2000 Dec; 26(6):411-27. PubMed ID: 11139372
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Time-dependent effect of non-Hodgkin's lymphoma grade on disease-free survival of relapsed/refractory patients treated with high-dose chemotherapy plus autotransplantation.
    Fu P; van Heeckeren WJ; Wadhwa PD; Bajor DJ; Creger RJ; Xu Z; Cooper BW; Laughlin MJ; Gerson SL; Koç ON; Lazarus HM
    Contemp Clin Trials; 2008 Mar; 29(2):157-64. PubMed ID: 17707140
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reduced intensity allogeneic stem cell transplantation for low grade non-Hodgkin's lymphoma.
    Morris EC; Mackinnon S
    Best Pract Res Clin Haematol; 2005 Mar; 18(1):129-42. PubMed ID: 15694189
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma].
    Zhou SY; Shi YK; He XH; Zhang P; Dong M; Huang DZ; Yang JL; Zhang CG; Liu P; Yang S; Feng FY
    Ai Zheng; 2005 Apr; 24(4):465-9. PubMed ID: 15820071
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 73.